Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Linzagolix (Primary)
- Indications Endometriosis; Pelvic pain
- Focus Therapeutic Use
- Acronyms EDELWEISS; EDELWEISS 1
- Sponsors ObsEva
- 02 Dec 2021 According to an ObsEva media release, data from this study will be presented at the 7th Society of Endometriosis and Uterine Disorders (SEUD) Congress.
- 03 Jun 2020 Results published in the Fertility and Sterility
- 27 Apr 2020 Results presented at the 69th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists